A new PPARα/γ co-agonist for the treatment of dyslipidemia

被引：0
|
作者：
Clay, C [1 ]
Tigon, X [1 ]
Ding, S [1 ]
Braileanu, G [1 ]
Hansen, B [1 ]
机构：
[1] Univ Maryland, Baltimore, MD 21201 USA
来源：
ATHEROSCLEROSIS SUPPLEMENTS | 2004年 / 5卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：25 / 25
页数：1
相关论文
共 50 条
  • [31] THE CO-AGONIST CONCEPT - IS THE NMDA-ASSOCIATED GLYCINE RECEPTOR SATURATED IN-VIVO
    WOOD, PL
    LIFE SCIENCES, 1995, 57 (04) : 301 - 310
  • [32] The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
    Kimberley El
    Jonathan D. Douros
    Francis S. Willard
    Aaron Novikoff
    Ashot Sargsyan
    Diego Perez-Tilve
    David B. Wainscott
    Bin Yang
    Alex Chen
    Donald Wothe
    Callum Coupland
    Mattias H. Tschöp
    Brian Finan
    David A. D’Alessio
    Kyle W. Sloop
    Timo D. Müller
    Jonathan E. Campbell
    Nature Metabolism, 2023, 5 : 945 - 954
  • [33] The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
    El, Kimberley
    Douros, Jonathan D.
    Willard, Francis S.
    Novikoff, Aaron
    Sargsyan, Ashot
    Perez-Tilve, Diego
    Wainscott, David B.
    Yang, Bin
    Chen, Alex
    Wothe, Donald
    Coupland, Callum
    Tschoep, Mattias H.
    Finan, Brian
    D'Alessio, David A.
    Sloop, Kyle W.
    Mueller, Timo D.
    Campbell, Jonathan E.
    NATURE METABOLISM, 2023, 5 (06) : 945 - +
  • [34] The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine
    Zhang, Hai Xia
    Hyrc, Krzysztof
    Thio, Liu Lin
    JOURNAL OF PHYSIOLOGY-LONDON, 2009, 587 (13): : 3207 - 3220
  • [35] Beneficial Effects of a Dual Acting GLP-1R/Glucagon Receptor Co-Agonist in the Treatment of Hepatic Regeneration in NAFLD
    Pilar Valdecantos, M.
    Pardo, Virginia
    Alvarez, Carmen
    Grimsby, Joseph
    Rondinone, Cristina M.
    Valverde, Angela M.
    DIABETES, 2014, 63 : A295 - A295
  • [36] Tesaglitazar.: Treatment of type 2 diabetes, treatment of metabolic syndrome, PPARα/PPARγ agonist
    McIntyre, JA
    Castañer, J
    Bayés, M
    DRUGS OF THE FUTURE, 2003, 28 (10) : 959 - 965
  • [37] Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes
    Benardeau, Agnes
    Benz, Joerg
    Binggeli, Alfred
    Blum, Denise
    Boehringer, Markus
    Grether, Uwe
    Hilpert, Hans
    Kuhn, Bernd
    Maerki, Hans Peter
    Meyer, Markus
    Puentener, Kurt
    Raab, Susanne
    Ruf, Armin
    Schlatter, Daniel
    Mohr, Peter
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (09) : 2468 - 2473
  • [38] The pharmacological stimulation of NMDA receptors via co-agonist site:: an fMRI study in the rat brain
    Panizzutti, R
    Rausch, M
    Zurbrügg, S
    Baumann, D
    Beckmann, N
    Rudin, M
    NEUROSCIENCE LETTERS, 2005, 380 (1-2) : 111 - 115
  • [39] Probing the Modulation of Acute Ethanol Intoxication by Pharmacological Manipulation of the NMDAR Glycine Co-Agonist Site
    DeBrouse, Lauren
    Hurd, Benita
    Kiselycznyk, Carly
    Plitt, Aaron
    Todaro, Alyssa
    Mishina, Masayoshi
    Grant, Seth G. N.
    Camp, Marguerite
    Gunduz-Cinar, Ozge
    Holmes, Andrew
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2013, 37 (02) : 223 - 233
  • [40] Control of Appetite and Food Preference by NMDA Receptor and Its Co-Agonist d-Serine
    Sasaki, Tsutomu
    Matsui, Sho
    Kitamura, Tadahiro
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (07)
12345